Effects of intranasal estradiol treatment on serum paraoxonase and lipids in healthy, postmenopausal women

Gynecologic and Obstetric Investigation

Volumn 61, Issue 4, 2006, Pages 203-207

  Fenkci, Ibrahim Veysel ^a,c   Serteser, Mustafa ^a   Fenkci, Semin ^b   Akyol, Ahmet Melih ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Intranasal 17 estradiol; Menopause; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN DEFICIENCY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ADULT; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN; LIPIDS; MIDDLE AGED; POSTMENOPAUSE;

EID: 33646741433     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091418     Document Type: Article

References (43)

1. Jensen J, Nilas L, Christiansen C: Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321-331.
2. Brousseau ME, Schaefer EJ: New targets for medical treatment of lipid disorders. Curr Atheroscler Rep 2002;4:343-349.
3. Blass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-2216.
4. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS: Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 2003;44:780-792.
5. La Du BN: Structural and functional diversity of paraoxonases. Nat Med 1996;2:1186-1187.
6. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
7. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-154.
8. Betteridge DJ: What is the oxidative stress? Metabolism 2000;49(suppl 1):3-8.
9. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN: Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-335.
10. Mackness B, Durrington PN, McElduff P, Yarnell J, Azam N, Watt M, Mackness B: Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-2779.
11. Sendag F, Karadadas N, Ozsener S, Bilgin O: Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. Arch Gynecol Obstet 2002;266:38-43.
12. Ranta V, Oksanen H, Arrenbrecht S, Ylikorkala O: National differences in lipid response to postmenopausal hormone replacement therapy. Maturitas 2002;42:259-265.
13. Devissaguet JP, Brion N, Lhote O, Deloffre P: Pulsed estrogen therapy: pharmacokinetics of intranasal 17β-estradiol (S21400) in post-menopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-271.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
15. Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment evaluation uses the computer program. Diabetes Care 1998;21:2191-2192.
16. Eckerson HW, Romson J, Wyte C, La Du B: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-227.
17. Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
18. De Aloysio D, Gambacciani M, Meschia M, Pansini F, Bacchi Modena A, Bolis PF, Massobrio M, Maiocchi G, Peruzzi E: The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study group. Atherosclerosis 1999;147:147-153.
19. Von Eckardstein A, Nofer JR, Assmann G: High-density lipoproteins and atherosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27.
20. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-663.
21. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC: Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998;9:319-324.
22. Aviram M: Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999;5:381-386.
23. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-20966.
24. Maor I, Kaplan M, Hayek T, Vaya J, Hoffman A, Aviram M: Oxidized monocyte-derived macrophages in aortic atherosclerotic lesion from apolipoprotein E-deficient mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem Biophys Res Commun 2000;269:775-780.
25. Pentikainen MO, Oorni K, Ala-Korpela M, Kovanen PT: Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000;247:359-370.
26. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM: Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002;106:484-490.
27. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774-784.
28. 2 activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003;23:461-467.
29. Topcuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topcuoglu D: The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 2005;205:79-86.
30. Erenus M, Karakoc B, Gurler A: Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001;4:228-234.
31. Chen FP, Lee N, Soong YK, Huang KE: Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause 2001;8:347-352.
32. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-1852.
33. Godsland IF: Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915.
34. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
35. Darko DA, Dornhorst A, Kennedy G, Mandeno RC, Seed M: Glycaemic control and plasma lipoproteins in menopausal women with type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. Diabetes Res Clin Pract 2001;54:157-164.
36. Kiran H, Kiran G, Ekerbicer HC, Guven AM, Kilinc M: Effects of oestrogen replacement therapy on serum C-reactive protein levels in hysterectomised women. Aust NZ J Obstet Gynaecol 2004;44:131-134.
37. Eckerson HW, Romson J, Wyte C, La Du BN: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-227.
38. Wild RA: Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol 1994;12:38-44.
39. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
40. Boemi M, Leviev I, Sirolla C, Fieri C, Marra M, James RW: Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first-degree relatives. Influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001;155:229-235.
41. Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K: Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 2001;50:657-660.
42. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-480.
43. Rosenblat M, Grunfeld O, Hayek T, Aviram M: Serum paraoxonase activity and the extent of lipid peroxidation are not affected by increased levels of human apolipoprotein A-I: studies in transgenic mice. Clin Chem Lab Med 2002;40:9-14.